|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| M |
MUSCULOSKELETAL PRODUCTS |
| M1A1 |
ANTI-INFLAMMATORY
Products that are used in the treatment of unspecified inflammation. For products that are only used to treat arthritis see the Antiarthritic (M2) sections. Agents under development include salicylates eg ASA thioesters, indometacin-like products, propionic acid derivatives eg ibuprofen, 5-lipoxygenase and cyclo-oxygenase inhibitors, steroids eg glucocorticoid agonists, monoclonal antibodies and phosphodiesterase (PDEs) inhibitors. |
| M1A2 |
ANTI-INFLAMMATORY, TOPICAL
Topically-applied treatments for musculoskeletal disorders including topical formulations of NSAIDs and steroids. If the products are also used in the treatment of arthritis, they will also appear in the Antiarthritic sections (M2C or M2Z). |
| M2C |
ANTIARTHRITIC, IMMUNOLOGICAL
Compounds which act via the immune system to alleviate the symptoms of arthritis. Some of these products may also be used in the treatment of muscular dystrophy, psoriatic arthritis and other general autoimmune diseases. Products in development include immunosuppressants, antibodies, cytokines receptor antagonists and inhibitors to the selectins — endothelial-leucocyte adhesion molecule-1 (ELAM-1), vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). |
| M2Z |
ANTIARTHRITIC, OTHER
Compounds for the treatment of arthritis including rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, which do not act via the immune system (see M2C). Products under investigation include NSAIDs eg inhibitors of cyclo-oxygenase and lipoxygenase, corticosteroids and metalloprotease inhibitors. |
| M3 |
MUSCLE RELAXANT
Centrally- and peripherally-acting muscle relaxants including neuromuscular blockers, centrally-acting drugs eg GABA analogues and dopaminergic derivatives, non-centrally-acting compounds eg vanilloids and purified forms of botulinum toxin A. |
| M4A |
ANTIGOUT
Gout is an inflammatory condition produced by hyperuricaemia and subsequent deposition of urate crystals in and around joints and tendons. Products under development include xanthine oxidase inhibitors and dual cyclo-oxygenase and lipoxygenase inhibitors. |
| M5A |
OSTEOPOROSIS TREATMENT
Drugs that are used for the treatment of plasma hypercalcaemia, a condition associated with osteoporosis, osteodystrophy and Paget's disease, amongst others. Compounds in development include gonadal hormones eg HRT combinations, formulations of calcitonin, diphosphates, vitamin D3 derivatives, growth hormone peptides, human parathyroid hormone (PTH) and insulin-like growth factor (IGF) carrier protein. |
| M5Z |
MUSCULOSKELETAL
Compounds with a musculoskeletal action not covered by any other category in Pharmaprojects including products for muscular dystrophy, myasthenia gravis and for fractures and bone repair (see also M5A). Agents under investigation include bone cell stimulating substances, growth hormone releasing peptides and thiolprotease inhibitors. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home